CryoCath launches new catheter in Italy, Belgium and Spain

Arctic Front, the company’s lead product for the treatment of paroxysmal atrial fibrillation (PAF), is said to be a cryoablation balloon catheter that allows physicians to safely and effectively isolate all four pulmonary veins for the treatment of PAF.

Jan Keltjens, president and CEO of CryoCath, said: “The introduction of Arctic Front in Italy, Belgium and Spain provides us with an exciting opportunity to deliver the benefits of our breakthrough therapy to a larger patient population and drive one of our key corporate goals of explosive and profitable revenue growth in Europe.

“By expanding our already strong presence in Europe, we are continuing to drive the adoption of our Arctic Front system worldwide.”